Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897507 · ClinicalTrials.gov registry record
DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia
A clinical trial of Recurrent Childhood Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia in Remission, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 520
- Enrollment target
- 1
- Study location
NCT00897507 is a study of Recurrent Childhood Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia in Remission that has completed, run by Children's Oncology Group. The registered enrollment target is 520 participants, above the 80-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (550% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00897507, a study of Recurrent Childhood Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia in Remission, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 520 participants
- Enrollment target
- 1
- Study location
Study Summary
This laboratory study is looking at DNA in tumor tissue samples from young patients with acute lymphoblastic leukemia. DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Pennsylvania
- Childrens Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2004-05-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00897507
The ClinicalTrials.gov registry entry for NCT00897507 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 80-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (550% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Childhood Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT00897507 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00897507 about?
NCT00897507 is a clinical study titled "DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia". This laboratory study is looking at DNA in tumor tissue samples from young patients with acute lymphoblastic leukemia. DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment
What is the current status of trial NCT00897507?
This trial is currently completed. The enrollment target is 520 participants. The study started on 2004-05-13.
What conditions does trial NCT00897507 study?
This clinical trial studies the following conditions: Recurrent Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission.
What interventions are being tested in trial NCT00897507?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT00897507?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00897507 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
RECRUITING · Phase 1
-
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
ACTIVE NOT RECRUITING · Phase 2
-
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
COMPLETED · Phase 1
-
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Childhood Acute Lymphoblastic Leukemia
All registered trials for this condition
Childhood Acute Lymphoblastic Leukemia in Remission
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.